Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

731
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
731
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignant B cells expressing SIRPα are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.

Leukemia·2026
Same author

POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.

Blood advances·2026
Same author

Multi-omics analysis reveals a unique epigenetic signature in <i>MYD88</i> wild-type Waldenström macroglobulinemia.

Haematologica·2025
Same author

Unraveling lymphoma-induced immune senescence.

Cancer cell·2025
Same author

Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts.

Blood cancer journal·2025
Same author

IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma.

Blood cancer discovery·2025

Related Experiment Video

Updated: Oct 14, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K

PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma.

Patrizia Mondello1, Stephen M Ansell1

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Cancer Cell
|November 5, 2021
PubMed
Summary

Molecular classification of diffuse large B cell lymphoma enables targeted therapies. A large genomic analysis identified molecular signatures predicting response to ibrutinib plus R-CHOP, advancing precision medicine.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Related Experiment Videos

Last Updated: Oct 14, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Diffuse large B cell lymphoma (DLBCL) classification has evolved, enabling targeted therapies.
  • Precision medicine in DLBCL focuses on oncogenic pathways and actionable mutations.
  • Understanding differential treatment responses is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To identify molecular signatures associated with varied responses to ibrutinib plus R-CHOP in DLBCL.
  • To advance the understanding of genomic drivers influencing treatment efficacy in DLBCL.

Main Methods:

  • Massive genomic analysis of DLBCL patient samples.
  • Correlation of genomic data with treatment response to ibrutinib plus R-CHOP.

Main Results:

  • Identification of putative molecular signatures linked to differential response.
  • Genomic insights into patient stratification for ibrutinib plus R-CHOP therapy.

Conclusions:

  • Molecular signatures can predict response to ibrutinib plus R-CHOP in DLBCL.
  • Genomic analysis is key to advancing precision medicine strategies for DLBCL.